Phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies and antiphospholipid syndrome

Junichi Kaburaki, Masataka Kuwana, Mihoko Yamamoto, Shinichi Kawai, Eiji Matsuura, Yasuo Ikeda

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A portion of anticardiolipin antibodies is defined as phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies and recognizes the conformationally altered β2-GPI which interacts with anionic phospholipids. We studied the clinical significance of IgG phospholipid-dependent anti-β2-GPI antibodies in patients with antiphospholipid syndrome (APS). The subjects consisted of 60 APS patients. IgG phospholipid-dependent anti-β2-GPI antibodies were detected by ELISA in 32 of the 60 patients (53%). Significantly higher incidences of prolonged APTT and lupus anticoagulants were found in patients with these anti-β2-GPI antibodies. Moreover, significantly lower incidences of malar rash, serositis, LE cell preparation and anti-Sm antibodies were found in patients with these anti-β2-GPI antibodies. It was found that 88% of the patients with these anti-β2-GPI antibodies satisfied less than five of the revised criteria items for the classification of SLE. These findings indicate the clinical characteristics of APS patients with IgG phospholipid-dependent anti-β2-GPI antibodies.

Original languageEnglish
Pages (from-to)105-110
Number of pages6
JournalInternal Medicine
Volume35
Issue number2
Publication statusPublished - Feb 1996
Externally publishedYes

    Fingerprint

Keywords

  • Anticardiolipin antibodies
  • Antiphospholipid antibodies
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Kaburaki, J., Kuwana, M., Yamamoto, M., Kawai, S., Matsuura, E., & Ikeda, Y. (1996). Phospholipid-dependent anti-β2-glycoprotein I (β2-GPI) antibodies and antiphospholipid syndrome. Internal Medicine, 35(2), 105-110.